Abstract
EGFR Inhibitors are used to treat Non-Small-Cell Lung Cancer (NSCLC) and colorectal cancer (CRC). A common side effect of EGFR Inhibitors is a follicular/pustular skin eruption. We report a case of gefitinib (Iressa) associated skin eruption. The treatment regimen consisted of triamcinolone 0.1% cream twice daily, clindamycin 1% lotion twice daily and sodium sulfacetamide lotion twice daily. The clinical presentation, etiology, and management options of EGFR Inhibitor associated skin eruptions are discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 368-369 |
| Number of pages | 2 |
| Journal | Journal of drugs in dermatology : JDD |
| Volume | 5 |
| Issue number | 4 |
| State | Published - Apr 2006 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Dermatology
Fingerprint
Dive into the research topics of 'Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver